The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Switching to venetoclax-based therapy after progression on covalent BTKis in CLL: expert opinion
Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, briefly discusses the potential benefits of using venetoclax-based regimens to treat patients with chronic lymphocytic leukemia (CLL) who progress on covalent BTK inhibitors. He also advises against using venetoclax-based regimens in patients with p53-disrupted CLL. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
